Our Pricing

Understanding Wegovy Doses: From Starter to Maintenance in the UK

Published on: June 03, 2026

Finding all wegovy doses UK online with clear guidance can be challenging when you're starting your weight management journey. At Cured Pharmacy, we provide the complete Wegovy dose range from £79.00 with UK prescribers supporting you through every stage from initial 0.25mg starter doses to the full 2.4mg maintenance dose, ensuring safe and effective treatment progression.

The Complete Wegovy Dose Escalation Schedule

Wegovy (semaglutide) follows a carefully structured dose escalation protocol designed to minimise gastrointestinal side effects whilst optimising weight loss outcomes [1]. The treatment begins at 0.25mg weekly and gradually increases over 16 weeks to reach the maintenance dose of 2.4mg weekly, which has demonstrated the most significant clinical benefits in the STEP trial programme.

This gradual escalation isn't arbitrary — it allows your body to adapt to semaglutide's effects on gastric emptying and appetite regulation [1]. Each dose level is maintained for four weeks before progression, giving your digestive system time to adjust whilst still delivering progressive weight loss at every stage. Clinical data shows that patients who follow this escalation schedule experience fewer treatment discontinuations due to side effects compared to rapid dose increases [2].

The standard UK-licensed escalation pathway progresses through six distinct dose levels: 0.25mg (weeks 1-4), 0.5mg (weeks 5-8), 1mg (weeks 9-12), 1.7mg (weeks 13-16), and finally 2.4mg from week 17 onwards as your maintenance dose [1]. Your UK prescriber may adjust this schedule based on your individual tolerance and response, occasionally extending time at a particular dose level if needed.

Wegovy Starter Doses: What to Expect in Weeks 1-8

The initial 0.25mg dose serves primarily as an introductory phase, allowing your body to begin adapting to semaglutide's mechanism of action [1]. During these first four weeks, many patients report modest appetite reduction and early weight loss of 1-3% body weight, though the primary goal at this stage is establishing tolerance rather than maximal efficacy.

Progression to 0.5mg at week 5 typically marks when patients notice more pronounced appetite suppression and sustained satiety between meals [2]. This dose level produces measurable GLP-1 receptor activation sufficient to influence both gastric emptying and central appetite pathways in the hypothalamus. Common experiences include feeling satisfied with smaller portion sizes and reduced food-related thoughts throughout the day.

These starter doses are critical for long-term treatment success. Research from the STEP-1 trial demonstrated that patients who completed the full escalation schedule achieved significantly greater weight loss at 68 weeks compared to those who discontinued early or skipped dose levels [2]. Subject to prescriber approval, your UK clinician will confirm you're ready to progress based on tolerability and any side effects experienced.

Managing Side Effects During Dose Escalation

Nausea, mild constipation, and occasional digestive discomfort are common during the first 8-12 weeks of treatment but typically diminish as your body adapts [1]. Eating smaller, more frequent meals and avoiding high-fat foods can significantly reduce these effects. If side effects persist beyond the first few days of a new dose level, your prescriber may recommend extending that dose for an additional 2-4 weeks before progressing further.

Mid-Range Doses: 1mg and 1.7mg Wegovy in the UK

The 1mg dose level, administered during weeks 9-12, represents a therapeutic threshold where clinical weight loss accelerates notably [2]. In STEP trial subgroup analyses, patients at this dose level averaged 8-10% body weight reduction from baseline, with many experiencing significant improvements in obesity-related comorbidities including blood pressure and lipid profiles.

Progression to 1.7mg at week 13 bridges the gap to full maintenance dosing, providing near-maximal GLP-1 receptor activation whilst still allowing physiological adjustment before the final increase [1]. This dose produces appetite suppression comparable to the 2.4mg maintenance level in approximately 60-70% of patients, though the higher maintenance dose consistently demonstrates superior outcomes in clinical trials measuring long-term weight loss maintenance.

At these mid-range doses, patients often report substantial behavioural changes around food — reduced cravings for energy-dense foods, natural portion control without conscious restriction, and improved satiety signals that align eating with genuine hunger rather than emotional or environmental triggers [2]. These neurohormonal effects reflect semaglutide's action on appetite-regulating centres in the brain, not just peripheral effects on digestion.

Wegovy Maintenance Dose: The 2.4mg Target in UK Treatment

The 2.4mg weekly maintenance dose represents the fully licensed therapeutic level for chronic weight management in the UK, supported by the most robust clinical evidence from the STEP programme [2]. In the landmark STEP-1 trial, patients receiving 2.4mg semaglutide achieved an average 14.9% body weight reduction over 68 weeks, compared to 2.4% with placebo — a clinically and statistically significant difference that led to MHRA licensing approval.

This maintenance dose is designed for long-term continuation, not as a temporary intervention [2]. Semaglutide's effects on weight are sustained only whilst treatment continues — discontinuation typically results in gradual weight regain as the neurohormonal appetite regulation diminishes. UK prescribers therefore approach Wegovy as a chronic disease management tool similar to medications for hypertension or diabetes, requiring ongoing treatment for sustained benefit.

Subject to prescriber approval and ongoing clinical assessment, patients remain on the 2.4mg maintenance dose indefinitely whilst it continues to provide benefit and is well-tolerated [1]. Some individuals achieve their weight goals before reaching maintenance dose and may remain on a lower level such as 1.7mg if this adequately maintains their weight loss, though this decision must be made collaboratively with your UK prescriber based on individual response and clinical parameters.

What Happens If You Miss the Maintenance Dose?

If you miss a 2.4mg maintenance dose and fewer than 5 days have passed, administer the missed dose as soon as you remember, then resume your regular weekly schedule [1]. If more than 5 days have elapsed, skip the missed dose entirely and administer your next dose on the regularly scheduled day. Do not double doses to compensate for missed injections, as this increases the risk of gastrointestinal side effects without improving efficacy.

All Wegovy Doses Available at Cured Pharmacy

At Cured Pharmacy, we maintain consistent stock of all Wegovy dose strengths to ensure uninterrupted treatment progression from starter through maintenance phases. Our transparent pricing starts from £79.00 per pen, with costs clearly displayed before your free clinical consultation begins — no hidden fees or surprise charges after prescriber approval.

Every Wegovy prescription requires clinical assessment by a UK-registered prescriber who will determine your appropriate starting dose and escalation schedule based on your medical history, current medications, and weight management goals [1]. Our online consultation takes under 3 minutes to complete and is reviewed by qualified clinicians, typically within 24 hours on working days. Once approved, your medication is dispensed from our UK-registered pharmacy (GPhC 9012511) in discreet, unmarked packaging.

We supply only genuine UK-licensed Wegovy pens manufactured by Novo Nordisk, each containing pre-filled semaglutide solution with the FlexTouch injection system. Your prescription will specify the exact dose strength and quantity needed for your current treatment phase, whether that's starter doses for initial weeks or maintenance supplies for ongoing treatment. Subject to prescriber approval, repeat prescriptions can be arranged to ensure seamless continuation without treatment gaps.

How to Start Your Wegovy Assessment

Begin by completing our free online consultation, which asks about your weight history, previous weight loss attempts, current health conditions, and medications. A UK prescriber reviews your responses to determine if Wegovy is clinically appropriate and safe for you. If approved, you'll receive a prescription for the appropriate starting dose, typically 0.25mg for treatment-naïve patients, with guidance on progression through subsequent dose levels over the following months.

Wegovy Doses vs Other Weight Loss Treatments Available in the UK

Wegovy's structured dose escalation to 2.4mg weekly distinguishes it from other GLP-1 treatments available through UK pharmacies [2]. Saxenda (liraglutide) requires daily injections starting at 0.6mg and escalating to 3mg daily over 5 weeks, offering more frequent dosing but a different pharmacokinetic profile with shorter duration of action. The daily injection requirement can be less convenient for some patients compared to Wegovy's once-weekly administration.

Newer dual-agonist treatments work through different mechanisms — activating both GIP and GLP-1 receptors — and follow their own escalation schedules distinct from Wegovy's semaglutide-based pathway [3]. These alternatives may produce greater average weight loss in clinical trials but are not necessarily more effective for every individual. Your response to any weight management medication depends on numerous factors including genetics, baseline metabolic health, adherence, and lifestyle modifications undertaken alongside pharmacotherapy.

The choice between available treatments should be guided by your UK prescriber based on your medical profile, previous treatment responses, injection frequency preferences, and cost considerations [1][2]. At Cured Pharmacy, our clinical team can discuss all licensed options during your consultation, ensuring you start the treatment most likely to succeed for your individual circumstances. All prescription weight management medications require ongoing clinical monitoring and are most effective when combined with reduced-calorie nutrition and increased physical activity.

Scientific References

1. Electronic Medicines Compendium. (2023). Wegovy 2.4 mg solution for injection in pre-filled pen - Summary of Product Characteristics. Medicines and Healthcare products Regulatory Agency. https://www.medicines.org.uk/emc/product/13799 [accessed 13 August 2026]
2. Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., Wharton, S., Yokote, K., Zeuthen, N., & Kushner, R. F. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
3. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., & Stefanski, A. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038 [accessed 13 August 2026]
4. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
5. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
6. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Weight loss results vary between individuals and depend on multiple factors including adherence, diet, physical activity, and baseline health status.